Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Information on prescribing disease-modifying anti-rheumatic drugs

From: Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement

  Total DMARD prescribers a DMARD non-prescribers
  n= 266 b n= 217 n= 49
Initial prescription, continuation, or both    
   First only   20 (9%)  
   Continuation only   98 (45%)  
   Both   99 (46%)  
Prescribed DMARDs    
   Methotrexate   195 (90%)  
   Hydroxychloroquine   171 (79%)  
   Sulfasalazine   135 (62%)  
   Leflunomide   43 (20%)  
   Gold   35 (16%)  
   Azathioprine   54 (25%)  
   Cyclosporine   32 (15%)  
   Abatacept   8 (4%)  
   Etanercept   64 (29%)  
   Infliximab   56 (26%)  
   Rituximab   20 (9%)  
   Adalimumab   43 (20%)  
   Certolizumab pegol   2 (1%)  
   Golimumab   1 (0%)  
Type of DMARDs prescribeda    
   Biologic and non-biologic DMARDs   96 (44%)  
   Non-biologic DMARDs only   118 (54%)  
   Biologic DMARDs only   2 (1%)  
Factors that make patients inappropriate candidates for DMARDs    
   No need (well controlled without DMARDs) 131 (49%) 110 (51%) 21 (43%)
   Too sick to take a DMARD 92 (35%) 78 (36%) 14 (29%)
   Side effects of DMARDs too problematic 148 (56%) 128 (59%) 20 (41%)
   Drug interactions 83 (31%) 74 (34%) 9 (18%)
   Drug cost and monitoring are too high 142 (55%) 115 (53%) 27 (55%)
   Cannot get laboratory monitoring 20 (8%) 17 (8%) 3 (6%)
Best time to initiate DMARDs    
   After a trial of NSAIDs or steroids 92 (35%) 75 (35%) 17 (35%)
   Within the first 6 months of diagnosis 159 (60%) 132 (61%) 27 (55%)
   At least 6 months after diagnosis 13 (5%) 9 (4%) 4 (8%)
Comfort level starting a DMARDc    
   Very comfortable 23 (9%) 23 (11%) 0 (0%)
   Somewhat comfortable 79 (30%) 73 (34%) 6 (12%)
   Somewhat uncomfortable 112 (42%) 89 (41%) 23 (47%)
   Very uncomfortable 50 (19%) 30 (14%) 20 (41%)
Comfort level continuing a DMARDd    
   Very comfortable 75 (28%) 71 (33%) 4 (8%)
   Somewhat comfortable 130 (49%) 107 (50%) 23 (47%)
   Somewhat uncomfortable 54 (20%) 37 (17%) 17 (35%)
   Very uncomfortable 6 (2%) 1 (0%) 5 (10%)
  1. aOne prescriber did not fill in types of disease-modifying anti-rheumatic drugs (DMARDs). bOne missing response. cThree missing responses. dTwo missing responses. NSAID, non-steroidal anti-inflammatory drug.